Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 (Iparomlimab + Tuvonralimab) plus HAIC in unresectable or metastatic intrahepatic cholangiocarcinoma
ChiCTR2600124378Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of QL1706 in intrahepatic cholangiocarcinoma (ICC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Objective Response Rate (ORR). Started May 2026; status: recruiting.
02
Drugs
QL1706
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2600124378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124378.